



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Invited Review Article

## Reflections of an aging free radical

Barry Halliwell

Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Centre for Life Sciences, #05-01A, 28 Medical Drive, 117456, Singapore

## ARTICLE INFO

## Keywords:

Antioxidant  
Free radical  
Catalytic iron  
Ferroptosis  
Plants  
Ascorbate-glutathione cycle  
Hydrogen peroxide  
Ergothioneine

## ABSTRACT

In this mini-reflection, I explain how during my doctoral work in a Botany Department I first became interested in  $H_2O_2$  and later in my career in other reactive oxygen species, especially the role of “catalytic” iron and haem compounds (including leghaemoglobin) in promoting oxidative damage. The important roles that  $H_2O_2$ , other ROS and dietary plants play in respect to humans are discussed.

I also review the roles of diet-derived antioxidants in relation to human disease, presenting reasons why clinical trials using high doses of natural antioxidants have generally given disappointing results. Iron chelators and ergothioneine are reviewed as potential cytoprotective agents with antioxidant properties that may be useful therapeutically. The discovery of ferroptosis may also lead to novel agents that can be used to treat certain diseases.

## 1. Introduction

I was honoured and delighted to be asked to give a special lecture at the meeting of the Society for Free Radical Research International (SFRI) to be held in Taiwan March 17–20, 2020, and settled on a lecture title of “Reflections of an Ageing Free Radical”. I was even more honoured when asked to write an article based around that talk for *Free Radic. Biol. Med.*, a leading journal in which I have already published 35 papers in my career, cited a grand total of 6259 times (based on *Google Scopus*, Sep 2020). I was equally honoured when in 2008 I received the Lifetime Achievement Award from the Society for Redox Biology and Medicine and the paper I wrote subsequently for *Free Radic. Biol. Med.* “The Wanderings of a Free Radical” [1] has also been highly cited (511 times as of *Google Scopus* on Sep 14, 2020). Unfortunately, COVID-19 led to the cancellation of the Taiwan meeting, like many others, and has caused consternation worldwide. There is hope that cytoprotective agents with antioxidant properties may have some value in treating the many side effects of infection by this horrible virus [2–4]. The editors of *Free Radic. Biol. Med.* asked me to still go ahead with the manuscript, so here it is.

## 2. My early days

As “The Wanderings of a Free Radical” explains [1], my D. Phil. (the Oxford term for PhD) from the Botany School of Oxford University was on plant metabolism (Fig. 1). During it, I showed that  $H_2O_2$  plays a key

role in plant metabolism (Fig. 1); thus I became deeply interested in the field of  $H_2O_2$  and oxygen radicals at a time when few people cared about it [1,5,6]. Of course, interest in the field has exploded since. Cross contamination of organelles with catalase from different subcellular compartments was a key part of my work (Fig. 1) and contamination of reagents (including commercial catalase with SOD [7]) is still a problem that plagues us today [1,7,8]. We also discovered during my thesis work that there is a chemical reaction between Good’s buffers and flavin mononucleotide (FMN) that can generate  $H_2O_2$  [9]; the buffer you use can often affect your results.

## 3. Hydrogen peroxide is ubiquitous

I always find it amusing when I read papers where a few  $\mu M$   $H_2O_2$  is allegedly causing severe cytotoxicity.  $H_2O_2$  is a very important signaling molecule *in vivo*: the late Professor Roy Burdon in Scotland was an early pioneer in this work [10] and many others have made substantial contributions [11–14]. This employment of  $H_2O_2$  for useful biochemical roles is in part because of its limited reactivity (at least in the absence of transition metal ions, as discussed below). Like superoxide [8,15,16],  $H_2O_2$  is very selective in the molecules that it can react with directly. Few people realize that  $H_2O_2$  is present at high levels (sometimes  $>100 \mu M$ ) in such beverages as tea and coffee, although adding milk decreases the levels (Fig. 2) [17,18].  $H_2O_2$  is readily generated in the laboratory in cell culture media (the amounts depending on the media used) [19–21] and by photochemical reactions involving flavins [9,22].

E-mail address: [bchbh@nus.edu.sg](mailto:bchbh@nus.edu.sg).

<https://doi.org/10.1016/j.freeradbiomed.2020.10.010>

Received 24 August 2020; Received in revised form 6 October 2020; Accepted 8 October 2020

Available online 13 October 2020

0891-5849/© 2020 Elsevier Inc. All rights reserved.

## THE BIOCHEMISTRY OF PLANT PEROXISOMES

B. Halliwell

St. Cross' College

A thesis submitted for the degree of  
 Doctor of Philosophy in the  
 University of Oxford

Long Vacation, 1973



Can you spot the younger me in the photo?

(Note the thesis had to be hand-typed with carbon paper; the original went to the examiners and mine is a carbon copy)  
 Photograph courtesy of Professor Chris Leaver


**Fig. 1.** The front page of my D. Phil. thesis and a photograph of the graduating class. Can you spot the younger me in the photo? (Note the thesis had to be hand-typed with carbon paper; the original went to the examiners and mine is a carbon copy). Photograph courtesy of Professor Chris Leaver.

**Abstract**

Leaves of spinach (*Spinacia oleracea* L.) and other plants readily catalyse the oxidation of formate to  $\text{CO}_2$ . The enzymic mechanisms by which leaves convert formate to  $\text{CO}_2$  have not been fully established.

In the first part of this thesis, a detailed study of the properties and mechanism of formate oxidation in leaves of spinach and spinach-beet is described. Studies of the effects of catalase, catalase inhibitors and  $\text{H}_2\text{O}_2$  led to the conclusion that the peroxidatic action of catalase was responsible for formate oxidation at pH 5 in all fractions. *In vivo*, this activity takes place in peroxisomes. **Its apparent location in chloroplasts and mitochondria is shown to be an artefact due to the generation of  $\text{H}_2\text{O}_2$  by these organelles and the presence of contaminating catalase.**

The pathways by which formate is produced in plant tissues have been the subject of much previous investigation. Glyoxylate is a good precursor of formate when supplied to plant tissues (Cossins & Sinha, 1965), and so formate could be produced from this compound during photorespiration. It was found that **peroxisomes could catalyse the decarboxylation of glycollate and glyoxylate.** Detailed studies of these reactions, led to the conclusion that **these activities were due to the generation of  $\text{H}_2\text{O}_2$  in peroxisomes by the action of glycollate oxidase, followed by non-enzymic reaction of  $\text{H}_2\text{O}_2$  with glyoxylate, producing  $\text{CO}_2$  (from the carboxyl group) and formate.** This occurs because the peroxisomal catalase is unable to completely destroy  $\text{H}_2\text{O}_2$ , consistent with the observations of other workers on different systems.



**Fig. 2. A:** Hydrogen Peroxide Generation by Beverages. **B:** The Effect of Milk. H<sub>2</sub>O<sub>2</sub> is present at high levels in freshly-brewed beverages and levels increase with time. Adding 10% (v/v) milk decreases H<sub>2</sub>O<sub>2</sub> levels. Data reproduced from Ref. [18] with publisher’s permission.

**Table 1**

Measurement of hydrogen peroxide in freshly voided human urine samples and after 3.5 h incubation at room temperature.

Gender of subject	[H <sub>2</sub> O <sub>2</sub> ] in fresh urine (µM)	[H <sub>2</sub> O <sub>2</sub> ] in urine after 3.5 h incubation at room temperature	% Increase
Female	8.6	10.1	17
Female	5.8	9.9	71
Male	11.7	21.1	80
Female	6.7	9.4	40
Male	18.4	20.6	12
Female	22.3	27.1	22
Female	11.7	28.0	139

Data taken from Ref. [24].


Having read an earlier paper by Varma et al. [23], we decided to use an oxygen electrode and other methods to investigate levels of H<sub>2</sub>O<sub>2</sub> in human urine (Fig. 3). Levels were very variable between subjects (e.g. Table 1) and increased on standing, to an extent decreased by adding SOD, suggesting that some of the H<sub>2</sub>O<sub>2</sub> generation was by O<sub>2</sub><sup>•-</sup>-dependent autoxidation reactions within the urine [24]. The levels we observed were substantial: Varma et al. [23] found higher levels, probably because their assay involved 30min incubation, whereas our experiments used a shorter time (Fig. 3). Many other groups have since confirmed the presence of H<sub>2</sub>O<sub>2</sub> in human urine (e.g. Ref. [25–27]). The actual levels of H<sub>2</sub>O<sub>2</sub> in urine in the bladder *in vivo* are uncertain: much of the H<sub>2</sub>O<sub>2</sub> may be generated when the urine is exposed to atmospheric O<sub>2</sub> levels when voided and any H<sub>2</sub>O<sub>2</sub> generated in the bladder *in vivo* may diffuse into the epithelial cells for catabolism. Interestingly, levels of urinary H<sub>2</sub>O<sub>2</sub> increase after drinking instant coffee [28–30], probably because autoxidisable compounds from the coffee are excreted in the urine [30]. By contrast, green tea contains lower (but still substantial [Fig. 2]) levels of H<sub>2</sub>O<sub>2</sub> than coffee but drinking it does not increase urinary H<sub>2</sub>O<sub>2</sub> levels [30].

Indeed, H<sub>2</sub>O<sub>2</sub> and other reactive oxygen species (ROS) played key roles in human evolution (reviewed in Ref. [8,31–33]). They continue to do so throughout human development, starting from a gleam in your fathers’ eye, leading to fertilization and all that follows [8,34–39]; I have attempted to summarize this in Fig. 4. Reactive oxygen species are also essential in protection against infection and in the regulation of inflammation, sometimes pro-inflammatory and sometimes the opposite [40,41].

**4. In praise of plants, and a failed experiment with bananas**

I am never sorry that I completed a D. Phil. in a Botany School, because plants are of the greatest importance in the ROS/antioxidant field (Table 2). Working with Christine Foyer as my first PhD student, we postulated the ascorbate-glutathione cycle as the major mechanism by which chloroplasts dispose of H<sub>2</sub>O<sub>2</sub> [1,42,43], see Fig. 5. Before working on this cycle we were attempting to purify an oxalate oxidase enzyme from banana. Extracts of this fruit had high oxalate oxidase activity, but we could never get it purified, so made the lucky decision (in retrospect) to change topic to the ascorbate-glutathione cycle. During this work, we found that oxalate can easily be decarboxylated non-enzymically in the presence of flavins under normal laboratory lighting conditions, and H<sub>2</sub>O<sub>2</sub> is involved yet again [22]. My laboratory later proposed that H<sub>2</sub>O<sub>2</sub> serves to regulate CO<sub>2</sub> fixation in the chloroplast by inactivation of the Calvin cycle enzyme fructose bisphosphatase, whose activity can then be restored by the thioredoxin system [46]. Christine (Fig. 5) has gone on to have a very distinguished career in the plant field, with numerous awards and impactful publications [47].

One of the few things (and there aren’t many!) that nutritionists are fairly sure of is that plant-rich diets seem to promote health, lessening the risk of developing such age-related diseases as dementia, type 2 diabetes, and certain cancers. No one knows why, although the antioxidants present are often implicated as an explanation (Table 2). It could



**Fig. 3.** Hydrogen peroxide is present in human urine. A sample of freshly-voided human urine was placed in the chamber of an oxygen electrode. At point A, buffer (phosphate-buffered saline PBS) pH 7.4 was added and at point B, urine was added. Freshly-voided urine has low O<sub>2</sub> levels, hence the decrease. At point C, catalase dissolved in PBS (103 units of catalase) was injected through the cap. Note the immediate burst of O<sub>2</sub> evolution. Adapted from Ref. [24]. The O<sub>2</sub> electrode method to measure H<sub>2</sub>O<sub>2</sub> is not very sensitive, but it is fast and simple; other methods (especially peroxidase-based ones) are susceptible to interference by compounds present in urine [8].




Fig. 4. A ROS view of the human life cycle.

ROS are essential for all aspects of the human life cycle, from conception and development until ageing and death [8,11–13,32–39]. There is a fine balance between their essentiality and the ability of too many of them to cause harm.

Table 2

Plants are essential to humans.


- Supply oxygen
- Supply diet-derived antioxidants (ascorbate, tocopherols, carotenoids, flavonoids, other phenols, ergothioneine)
- Diets rich in plants are associated with lower disease risk (some cancers, diabetes, cardiovascular, dementia, among others). No one knows exactly why.

even be the opposite: plants can contain high levels of phytoprostanes and aldehydes [48–50], perhaps upregulating endogenous defence systems in a hormetic response. Certain amounts of ascorbate and vitamin E, which both originate from plants, are essential in the diet but the optimal amounts in the human diet are uncertain. The RDA set for ascorbate in different countries is variable, indicative of the modest scientific database on which it is calculated [51–53], whereas the RDA set for vitamin E (~15 mg/day) is still uncertain but has some scientific support [54,55]. However, administering higher doses of ascorbate or vitamin E to humans has not shown convincing evidence of general benefit in the prevention or treatment of human disease, although there may be some benefit of vitamin E in cardiovascular disease for small sub-groups of patients [1,8,56–59]. Whereas, in my view, the only clearly-established *in vivo* role of vitamin E is as an antioxidant [8,55], ascorbate may well be more important *in vivo* as an enzyme cofactor: the most recent emphasis on this has been on the Tet dioxygenases, which start the process of DNA demethylation and hence regulate the metagenome [60,61]. The lack of ascorbate in many cell culture media (rarely added because it is unstable) is yet another example of how the cell culture process can lead to misleading results [19–21,62], in this case artefactually altering the metagenome. Perhaps the most important antioxidant role of ascorbate *in vivo* is its ability to scavenge oxidizing air pollutants in the respiratory tract [63,64].

## 5. A failure of antioxidants does not negate the importance of oxidative damage

Why have epidemiological studies administering high doses of vitamin E, C or  $\beta$ -carotene for the prevention or amelioration of human disease been so disappointing? Is it because oxidative damage is unimportant in the origin and progression of human disease? Data indicate that this is not so, especially for certain cancers, such as those related to chronic inflammation [8,65–67] and for neurodegenerative diseases such as Alzheimer [8,68–71] and Parkinson disease [8,72–74]. So why then have high-dose antioxidants failed to deter the development or progression of these conditions? Table 3 lists some possible explanations. To me, one of the most plausible explanations, as I have argued several times earlier [8,76–78] is that these high doses simply fail to further decrease oxidative damage levels *in vivo* (see Refs. [53,79–81] for other examples). Hence they couldn't be expected to be effective against diseases where oxidative damage is a key contributor, simply because they don't decrease it. Limited amounts of vitamins E and C are of course essential in the diet, but it may in fact be fortunate that mega-doses of them do not seem to exert greater antioxidant capacity *in vivo*, as otherwise the widespread use of supplements of them might cause side effects by interfering with essential cell signaling processes, human development (Fig. 4), and/or with the key role of ROS in our defence against pathogens by phagocytes and in the regulation of inflammation [8,40,41,82,83]. It is also true that, if ROS are important in human diseases, agents or approaches that do decrease oxidative damage should be beneficial, although they might create side-effects. Indeed, several factors that are known to affect the risk of human disease also modulate oxidative damage (Table 4). It may be that some (perhaps even all?) of the beneficial effects of controlling blood glucose, cholesterol, body weight etc are indeed due to decreased oxidative damage [77]. Thus if you are an obese diabetic, losing weight, controlling blood glucose and lipids and exercising more may be the best





**Fig. 5.** Foyer-Halliwell-Asada Cycle.

The ascorbate–glutathione cycle in chloroplasts. Enzymes involved: 1, ascorbate peroxidase; 2, dehydroascorbate reductase (reaction 2 can also occur non-enzymically at high pH—the pH of the stroma during photosynthesis may rise to as high as 8, due to formation of the proton gradient); 3, glutathione reductase. The first product of oxidation of ascorbate by ascorbate peroxidase is semidehydroascorbate (SDA); two SDA radicals can undergo disproportionation to form ascorbate and dehydroascorbate. NAD(P)H-dependent and ferredoxin-dependent mechanisms for reducing SDA also exist in chloroplasts. Thylakoid-bound ascorbate peroxidase can scavenge  $\text{H}_2\text{O}_2$  as it is produced, and the resulting SDA can be reduced by electrons from photosystem I. The cycle shown above has been called the Foyer–Halliwell–Asada cycle after the names of the two scientists who first proposed it [42] and the third who did much to establish evidence for its occurrence [44]. However, we should acknowledge the contribution of Groden and Beck, who discovered ascorbate peroxidase in chloroplasts [45]. Adapted from Ref. [8] with permission of Oxford University Press.

**Table 3**

Why did interventions with high dose antioxidants to treat or prevent human disease fail? Some possible explanations.

- They studied advanced disease and not development of disease (too late to be effective)
- They may have used too high a dose (Just because 15 mg of vitamin E is good for you, it doesn't mean that 15 g is a thousand times better). Many nutrients have an optimal intake, and higher doses are harmful: examples include  $\text{Na}^+$ , Zinc, Selenium and vitamin A.
- The populations were well-nourished; only subjects deficient would show benefit (e.g. Ref. [75]).
- They often used high doses of single agents which can affect the uptake/distribution of other agents (e.g. high dose  $\alpha$ -tocopherol, can interfere with uptake of  $\gamma$ -tocopherol,  $\beta$ -carotene can affect the uptake of other carotenoids)
- The antioxidants were administered over the wrong time scale
- For neurodegenerative diseases, the supplements did not raise brain levels.

antioxidant strategies rather than consuming high doses of antioxidants (Table 4).

A second important factor could be the timing of antioxidant administration. For example, antioxidants have been shown to protect against stroke-induced brain damage in a multiplicity of animal models (reviewed in Ref. [8,88,89]). However, they haven't proven effective in the treatment of stroke in humans [8,89–91]. In an animal model, the antioxidants are usually given prior to vessel occlusion, sometimes at carefully chosen time points afterwards [8,88,89]. However, when my research group worked with neurologists to study levels of oxidative damage in stroke patients, using a range of plasma biomarkers, levels were already very high when the patients were first examined (Fig. 6). Stroke onset (Fig. 6) is defined as the time when the patient is hospitalized and consent has been obtained to take samples. Usually it is

difficult to pinpoint the exact onset of the stroke, and much oxidative damage may already have been done by the time the patient enters the hospital, rendering antioxidant administration ineffective [92]. On a brighter note, we also observed that levels of oxidative damage remained high for a considerable time, which suggests that longer-term therapy with appropriate antioxidants (i.e. these that do decrease oxidative damage) might be beneficial (Fig. 6).

## 6. Revisiting irony

A second reason for the use of  $\text{H}_2\text{O}_2$  to regulate cellular processes is its ability to cross membranes, in part by diffusion through the lipid bilayer and in addition direct passage through some of the aquaporin proteins [8,96].

Iron and other transition metal ions play a key role in promoting oxidative damage, by converting fairly-benign species such as  $\text{H}_2\text{O}_2$  into more reactive and damaging ones (Table 5) and by promoting “autoxidation” reactions, speeding up the oxidation of thiols, NAD(P)H, ascorbate, dopamine and a multiplicity of other biomolecules [8,98,99]. Thus if  $\text{H}_2\text{O}_2$  passing through a lipid bilayer meets a “stray”  $\text{Fe}^{2+}$  ion,  $\text{OH}^*$  can be generated and lipid peroxidation can be initiated [8]. If the same thing happened during passage of  $\text{H}_2\text{O}_2$  through an aquaporin, the  $\text{OH}^*$  would immediately attack the protein, damaging it and affecting water transport. The body attempts to prevent such reactions (Table 5) by ensuring the safe sequestration of transition metal ions, especially iron, in non-redox-active forms. This is a very important antioxidant defence [8,98–100]. Indeed, the release of “catalytic iron” during tissue injury is a key promoter of oxidative damage [9,98–100]. This was a major early focus of my research, much of it with John Gutteridge, who is retired now but still thinks critically about the field [32,101]. The

**Table 4**

If antioxidants such as vitamins E, C or  $\beta$ -carotene rarely change oxidative damage levels in humans, what does?

Scenario	Suggested Strategy to minimize
• Obesity (Humans) ↑	Lose weight, exercise more <sup>a</sup>
• Hyperglycaemia (Humans) ↑	Control blood glucose
• High plasma LDL Cholesterol (Humans) ↑	Control LDL cholesterol
• High Cholesterol Diet (Rabbits and rats, humans possibly) ↑	Eat diet rich in fruits and vegetables
• Zinc Intake (Rabbits, some other animals, human data inconclusive) ↑	Maintain adequate zinc intake
• Body Iron Levels (Rabbits, rats, mice, maybe humans) ↓	Avoid iron supplements unless deficient
• Certain foods <sup>c</sup> (Humans, e.g. dark soy sauce, tomato) ↑	Eat diet rich in fruits and vegetables
• Diabetes (in some studies, not others) <sup>b</sup> ↓	
• Intake of polyunsaturated fatty acids (PUFAs) <sup>d</sup> (docosahexaenoic acid, possibly eicosapentaenoic acid) ↑	Eat fish regularly
• Cigarette smoking ↓	Avoid or minimize
• Sunlight (eye, skin) ↑	Avoid too much exposure
• Other environmental toxins? (such as O <sub>3</sub> , NO <sub>2</sub> , arsenic in water) ↑	Avoid if possible

↑ Increases oxidative damage, ↓ decreases oxidative damage.

Adapted from Ref. [77].

Footnotes.

<sup>a</sup> Exercise has benefits other than weight loss, some of them may be “antioxidant” by upregulating endogenous antioxidant defences [82,84,85].

<sup>b</sup> May depend on how well glucose and lipids have been normalized in the diabetic cohorts studied.

<sup>c</sup> It is essential to do appropriate controls in testing effects of foods, because the consumption of any food (antioxidant or not) can sometimes alter levels of certain biomarkers [86,87].

<sup>d</sup> Despite the propensity of PUFAs to oxidize *in vitro*, growing evidence suggests that they can minimize oxidative damage *in vivo*.

release of “catalytic” iron ions and their potential pro-oxidant effects have been implicated in many conditions, from side effects of cancer chemotherapy [102,103] and birth prematurity [104] to liver failure [105], and, of course, the iron overload diseases [106–109]. This awareness of the role of iron ions in promoting oxidative damage (Table 5) has unfortunately not (yet?) led to many therapeutic approaches in the treatment of diseases; the well-established chelating agent desferrioxamine (DFX), which binds iron ions in a redox-inactive form [110–112] has shown only modest, if any, promise in a few clinical studies [113]. It must be noted however that DFX accelerates the


oxidation of Fe<sup>2+</sup>, producing a short “burst” of O<sub>2</sub><sup>•-</sup> generation, and has various other redox properties ([112] and Table 6). Nevertheless, inhibition of iron-dependent oxidative damage seems to be its major action *in vivo* [112]. Another potentially-useful agent clinically is the protein lactoferrin [114–116], binding of iron to which renders the metal redox-inactive [117,118]. Deferiprone and deferasirox are also being studied [119,120]. Even the well-studied agent Ebselen may (among its other properties) be able to inhibit iron-induced oxidative damage, in this case by blocking iron transport into cells [121,122].

A novel and exciting aspect of the interplay of iron and ROS is the recent discovery of ferroptosis [123], which is turning out to play a key role in the pathology of many diseases, such that inhibitors of this process may have therapeutic potential [123–125]. Studies of ferroptosis have unearthed a novel mechanism by which the sequestration of iron can be achieved to decrease oxidative damage. Some breast cancer cell lines resistant to ferroptosis have increased the expression of prominin2, which promotes the formation of ferritin-containing multi-vesicular bodies and exosomes that transport iron out of the cell, decreasing the intracellular level of catalytic iron and thus inhibiting ferroptosis [126]. Studies in *Drosophila* and mice have revealed yet another mechanism; oligodendrocytes provide antioxidant defence to neurons by supplying them with ferritin heavy chain that can sequester catalytic iron [127].

## 7. Ironic burgers

A question asked in the early days of studying iron-ROS interactions was whether hemoglobin and other haem proteins are biological Fenton reagents, e.g. can they react with H<sub>2</sub>O<sub>2</sub> to produce OH<sup>•</sup>? [128]. If they did, the OH<sup>•</sup> would immediately attack the haem ring or the adjacent amino acid residues and would be unlikely to be released into free solution [8]. Nevertheless, it is indeed the case that haem and, in the presence of H<sub>2</sub>O<sub>2</sub>, haem proteins such as myoglobin, haemoglobin and cytochrome c can be powerful pro-oxidants, a process that is important *in vivo*, the kidney and brain being especially sensitive targets of oxidative damage by haem proteins [129,130]. There are two aspects to these pro-oxidant effects (Fig. 7). Haem proteins react with H<sub>2</sub>O<sub>2</sub> to generate Fe(IV) (ferryl) species that can damage biomolecules, but an excess of peroxide can degrade the haem and release catalytic iron capable of promoting OH<sup>•</sup> formation [131–133]. Interestingly, ascorbate can reduce ferryl species and prevent the former, but it can promote oxidative damage by released catalytic metal ions (Fig. 7).

In the 1980s, a distinguished plant biochemist, Alan Puppo, visited my laboratory (then at King’s College London), for a short period. He was very interested in the biochemistry of the legume root nodule, which contains the protein leghaemoglobin and suffers oxidative stress during senescence [134] (this paper was co-authored with Christine Foyer, a small world!). Alain and I studied carefully how leghemoglobin interacts with H<sub>2</sub>O<sub>2</sub>, concluding that the reactions can be described by the scheme presented in Fig. 7 [135,136]. This work may have taken on a new relevance recently. Leghemoglobin is now a key constituent of “impossible burgers” [137] and its toxicology has been carefully examined in short-term experiments [138]. However, its redox activity might merit more study in the light of the ability of other haem proteins to catalyse redox reactions in the gut and perhaps predispose to cancer development [139–141]: the assumption that “plant-derived is safe” is not always valid. Indeed, the lowering of the levels of catalytic iron during the great oxygenation event in the Earth’s history was one factor allowing aerobes to survive [8,31]. While talking about burgers, the meat in cooked hamburgers contains low levels of lipid oxidation products, much less so in cheeseburgers, the “cheeseburger paradox” [142].



**Fig. 6.** Oxidative damage in human ischemic stroke: a biomarker study.

Data taken from Ref. [92].

Note that levels of oxidative damage (as measured by plasma biomarkers) were already high when the first samples were taken and remained high even after clinical improvement. Control refers to age-matched healthy subjects. F<sub>2</sub>- and F<sub>4</sub>- isoprostanes are well established biomarkers of oxidative lipid damage and allantoin is a biomarker of oxidative degradation of urate [8,92–95].



**Table 5**

Iron promotes oxidative damage Adapted from Ref. [97] by courtesy of Oxford University Press.

Starting agent	More reactive species produced on addition of iron ions
H <sub>2</sub> O <sub>2</sub>	Hydroxyl radical (FENTON REACTION) (and possibly reactive oxo-metal ion species)
HOCl	OH <sup>•</sup>
Lipid peroxides	Peroxyl radicals, alkoxy radicals, cytotoxic aldehydes
Thiols (R–SH)	O <sub>2</sub> <sup>•-</sup> , H <sub>2</sub> O <sub>2</sub> , RS <sup>•</sup> , OH <sup>•</sup> , oxysulphur radicals
NAD(P)H	NAD(P) <sup>•</sup> , O <sub>2</sub> <sup>•-</sup> , OH <sup>•</sup>
Ascorbic acid	OH <sup>•</sup> , possibly O <sub>2</sub> <sup>•-</sup> , semidehydroascorbate radical
Norepinephrine serotonin, DOPA, dopamine	OH <sup>•</sup> , O <sub>2</sub> <sup>•-</sup> , carbon-centred or other radicals derived from the compound
Peroxynitrite (ONOO <sup>-</sup> )	NO <sub>2</sub> <sup>•</sup>

**Table 6**

Properties of desferrioxamine.

- Powerful chelator of Fe(III) (stability constant  $\sim 10^{31}$ )
- Chelates several other metal ions with stability constants several orders of magnitude lower (e.g. Al(III),  $\sim 10^{25}$ ; Cu<sup>2+</sup>,  $\sim 10^{14}$ ; Zn<sup>2+</sup>,  $\sim 10^{11}$ ); has been used to remove aluminium from dialysis patients.
- Reacts slowly with O<sub>2</sub><sup>•-</sup> or HO<sub>2</sub><sup>•</sup> ( $k_2 \approx 10^3 \text{M}^{-1} \text{s}^{-1}$ ) to form nitroxide radicals that can oxidize ascorbate, GSH and NAD(P)H
- Substrate for myoglobin/H<sub>2</sub>O<sub>2</sub> systems, nitroxide radical forms as ferryl haem is reduced
- Moderately good scavenger of peroxy (RO<sub>2</sub><sup>•</sup>) radicals in aqueous solution, again a nitroxide results.
- Reacts with tyr-O<sup>•</sup> radical ( $k_2 \approx 6.3 \times 10^6 \text{M}^{-1} \text{s}^{-1}$ ), a nitroxide again results
- Reacts fast with OH<sup>•</sup> ( $k_2 \approx 10^{10} \text{M}^{-1} \text{s}^{-1}$ ); nitroxide radicals are again produced, so desferrioxamine is an excellent OH<sup>•</sup> scavenger; ferrioxamine scavenges OH<sup>•</sup> with the same rate constant
- Does not react directly with ONOO<sup>-</sup>/ONOOH but can protect against damage by them by reacting quickly with CO<sub>3</sub><sup>•-</sup> ( $k_2 \approx 1.7 \times 10^9 \text{M}^{-1} \text{s}^{-1}$ ) and NO<sub>2</sub><sup>•</sup> radicals ( $k_2 \approx 7.6 \times 10^6 \text{M}^{-1} \text{s}^{-1}$ ). Nitroxide produced again.
- Inhibits iron-dependent lipid peroxidation and OH<sup>•</sup> generation from H<sub>2</sub>O<sub>2</sub> in most systems; ferrioxamine does not inhibit, so a control with this substance can distinguish protection by iron binding from protection by direct scavenging of RS
- Accelerates the oxidation of Fe<sup>2+</sup> solutions, by binding the resulting Fe(III) more tightly than it does Fe<sup>2+</sup>; this is the **ferroxidase** action of DFO, which produces O<sub>2</sub><sup>•-</sup>:  

$$\text{Fe}^{2+} - \text{DFO} + \text{O}_2 \rightarrow \text{Fe(III)} - \text{DFO} + \text{O}_2^{\bullet-}$$
- Penetrates only slowly into most animal cells; may enter by pinocytosis into lysosomes; poorly absorbed from gut but oral administration could conceivably be used to interfere with iron absorption.
- Can raise levels of HIF1- $\alpha$  and promote a cellular 'hypoxic response'

Most studies with desferrioxamine are carried out with the commercially available desferal (desferrioxamine B methanesulphonate).

Adapted from Ref. [8].


## 8. Hope for the future?

Ergothioneine, a thione-thiol with significant cytoprotective properties *in vitro*, some (but by no means all) of which may involve its antioxidant activity, was first discovered in the ergot fungus, hence the name (reviewed in Refs. [4,143–145]). It was extensively studied in the 1950s to early 1990s [142,146–148], including by us [149,150]. Interest in it waned until 2005, when a selective transporter (OCTN1) that brings ergothioneine into the body and distributes it to key tissues [151–153] was identified by Gründemann et al. [151,152]. Indeed, some evidence suggests that expression of OCTN1 may increase at sites of tissue injury to bring in more ergothioneine and raise its levels as a cytoprotective mechanism [154]. Levels of ergothioneine are decreased in several human diseases, and ergothioneine administered to animals seems to enter all body tissues and fluids, including the brain [146,147,155]. Ergothioneine appears safe for human consumption and accumulates in the animal and human body when administered [146–148,155,156]. Several questions remain, including whether it can really act as a significant antioxidant *in vivo* [156], perhaps only when it is accumulated to high levels [154]. Ergothioneine is, from our current knowledge, only made by fungi (especially several types of mushroom), certain bacteria and certain yeasts. Yet it is found in many foods; higher plants cannot make it but some of them may acquire it from fungi in the soil (reviewed in Ref. [144]). We are continuing to investigate its therapeutic potential [4,143,157]; it has also been suggested by others to protect against frailty [158,159], be elevated during human fasting as part of an antioxidant defence response [160] and be a “longevity vitamin” [161].

Returning to the subject of plants, do their beneficial health effects involve decreasing oxidative damage? Sometimes they may do (e.g. tomatoes [162,163]), sometimes no. There is no great mass of data to support the view that “whole plants” act as antioxidants *in vivo*. Plants load themselves with antioxidants because they are subject to severe oxidative stress as they produce O<sub>2</sub> during photosynthesis; they don't produce these antioxidants for the benefit of humans who eat plants [164].

## 9. Conclusion: an ageing free radical

I turn 71 years old in 2020 but my laboratory is still active, studying the biological role of ergothioneine [143,144] and the role of ROS in ageing, Parkinson disease, cardiotoxicity and dementia [157,165–167]. ROS do not cause ageing, but they regulate aspects of it carefully, as many other groups have shown. Nor will antioxidants prevent ageing. Our attempts to find antioxidants that slow ageing in *C. elegans* revealed that the ones that seemed to work were not acting by antioxidant mechanisms [165]. Can antioxidants that really work *in vivo* help human diseases? Maybe yes, maybe no, as Fig. 8 summarises. I have shown this figure before [1,8], but still think that it is worth repeating. Tissue



**Fig. 7.** Are Haem proteins Fenton reagents?.




Fig. 8. What is the significance of oxidative stress in human disease? Adapted from Ref. [8] with permission of Oxford University Press.

damage causes oxidative stress, which may worsen the damage (in which case agents that truly decrease oxidative damage *in vivo* will help) or trigger adaptations that minimize tissue injury (in which case such agents will not and may be deleterious). It all depends!

The field of free radicals/reactive species/antioxidants underpins all of human biology [8,11–14,31,164]. Just when I think the field is getting a bit old and boring, new things appear. One is ferroptosis, as mentioned earlier and more are likely in the works.

I have done all the h-index, papers in top journals, citations etc. They don't go away. In my last few years of research, I can do what I want in the lab and publish where I like. My hope is that ergothioneine and derivatives of it will turn out to be important therapeutic agents for humans. Time will tell.

#### Acknowledgement

I thank the distinguished Tan Chin Tuan family for the funding support for my Centennial Professorship.

#### References

- [1] B. Halliwell, The wanderings of a free radical, *Free Radic. Biol. Med.* 46 (2009) 531–542.
- [2] J.M. McCord, B.M. Hybertson, A. Cota-Gomez, K.P. Geraci, G. Gao, Nrf2 activator PB125® as a potential therapeutic agent against COVID-19, *Antioxidants* 9 (2020) 51.
- [3] H. Sies, M. Parnham, Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections, *Free Radic. Biol. Med.* 156 (2020) 107–112.
- [4] I.K. Cheah, B. Halliwell, Could ergothioneine aid in the treatment of coronavirus patients? *Antioxidants* 9 (2020) E595.
- [5] B. Halliwell, V.S. Butt, Oxidative decarboxylation of glycolate and glyoxylate by leaf peroxisomes, *Biochem. J.* 138 (1974) 217–224.
- [6] B. Halliwell, Oxidation of formate by peroxisomes and mitochondria from spinach leaves, *Biochem. J.* 138 (1974) 77–85.
- [7] B. Halliwell, Superoxide dismutase: a contaminant of bovine catalase, *Biochem. J.* 135 (1973) 379–381.
- [8] B. Halliwell, J.M.C. Gutteridge, *Free Radicals in Biology and Medicine*, fifth ed., Clarendon Press, Oxford, 2015. UK.
- [9] B. Halliwell, V.S. Butt, Flavin-monomonucleotide-sensitized photo-oxidation of glyoxylate in Good's buffers, *Biochem. J.* 129 (1972) 1157–1158.
- [10] R.H. Burdon, Control of cell proliferation by reactive oxygen species, *Biochem. Soc. Trans.* 24 (1996) 1028–1032.
- [11] M.P. Murphy, A. Holmgren, N.G. Larsson, B. Halliwell, C.J. Chang, B. Kalyanaraman, S.G. Rhee, P.J. Thornalley, L. Partridge, D. Gems, T. Nyström,

- V. Belousov, P.T. Schumacker, C.C. Winterbourn, Unraveling the biological roles of reactive oxygen species, *Cell Metabol.* 13 (2011) 361–366.
- [12] H. Sies, D.P. Jones, Reactive oxygen species (ROS) as pleiotropic physiological signalling agents, *Nat. Rev. Mol. Cell Biol.* 21 (2020) 363–383.
- [13] R.L. Levin, P.B. Chock, Redox pioneer: Professor Sue Goo Rhee, *Antioxidants Redox Signal.* (2020), <https://doi.org/10.1089/ars.2020.8137> (ahead of print).
- [14] K.M. Holmström, T. Finkel, Cellular mechanisms and physiological consequences of redox-dependent signalling, *Nat. Rev. Mol. Cell Biol.* 15 (2014) 411–421.
- [15] J. Imlay, The molecular mechanisms and physiological consequences of oxidative stress: lessons from a model bacterium, *Nat. Rev. Microbiol.* 11 (2013) 443–454.
- [16] M. Schwarzländer, S. Wagner, Y.G. Ermakova, V.V. Belousov, R. Radi, J. S. Beckman, G.R. Buettner, N. Demaurex, M.R. Duchon, H.J. Forman, M. D. Fricker, D. Gems, A.P. Halestrap, B. Halliwell, U. Jakob, I.G. Johnston, N. S. Jones, D.C. Logan, B. Morgan, F.L. Müller, D.G. Nicholls, S.J. Remington, P. T. Schumacker, C.C. Winterbourn, L.J. Sweetlove, A.J. Meyer, T.P. Dick, M. P. Murphy, The 'mitoflash' probe cpYFP does not respond to superoxide, *Nature* 514 (2014) E12–E14.
- [17] B. Halliwell, M.V. Clement, J. Ramalingam, L.H. Long, Hydrogen peroxide. Ubiquitous in cell culture and *in vivo*? *IUBMB Life* 50 (2000) 251–257.
- [18] L.H. Long, A.N.B. Lan, F.T.Y. Hsuan, B. Halliwell, Generation of hydrogen peroxide by "antioxidant" beverages and the effect of milk addition. Is cocoa the best beverage? *Free Radic. Res.* 31 (1999) 67–71.
- [19] B. Halliwell, Cell culture, oxidative stress, and antioxidants: avoiding pitfalls, *Biomed. J.* 37 (2014) 99–105.
- [20] B. Halliwell, Oxidative stress in cell culture: an under-appreciated problem, *FEBS Lett.* 540 (2003) 3–6.
- [21] L.H. Long, A. Hoi, B. Halliwell, Instability of, and generation of hydrogen peroxide by, phenolic compounds in cell culture media, *Arch. Biochem. Biophys.* 501 (2010) 162–169.
- [22] B. Halliwell, Non-enzymic catalysis of oxalate decarboxylation by light and flavins, *Biochem. J.* 129 (1972) 497–498.
- [23] S.D. Varma, P.S. Devamanoharan, Excretion of hydrogen peroxide in human urine, *Free Radic. Res. Commun.* 8 (1990) 73–78.
- [24] L.H. Long, P.J. Evans, B. Halliwell, Hydrogen peroxide in human urine: implications for antioxidant defense and redox regulation, *Biochem. Biophys. Res. Commun.* 262 (1999) 605–609.
- [25] Y. Sato, K. Ogino, N. Sakano, D.H. Wang, J. Yoshida, Y. Akazawa, S. Kanbara, K. Inoue, M. Kubo, H. Takahashi, Evaluation of urinary hydrogen peroxide as an oxidative stress biomarker in a healthy Japanese population, *Free Radic. Res.* 47 (2013) 181–191.
- [26] J.W. Yuen, I.F. Benzie, Hydrogen peroxide in urine as a potential biomarker of whole body oxidative stress, *Free Radic. Res.* 37 (2003) 1209–1213.
- [27] V. Gupta, P. Mahub, P.N. Nesterenko, B. Paull, A new 3D printed radial flow-cell for chemiluminescence detection: application in ion chromatographic determination of hydrogen peroxide in urine and coffee extracts, *Anal. Chim. Acta* 1005 (2018) 81–92.
- [28] L.H. Long, B. Halliwell, Coffee drinking increases levels of urinary hydrogen peroxide detected in healthy human volunteers, *Free Radic. Res.* 32 (2000) 463–467.
- [29] K. Hiramoto, T. Kida, K. Kikugawa, Increased urinary hydrogen peroxide levels caused by coffee drinking, *Biol. Pharm. Bull.* 25 (2002) 1467–1471.
- [30] B. Halliwell, L.H. Long, T.P. Yee, S. Lim, R. Kelly, Establishing biomarkers of oxidative stress. The measurement of hydrogen peroxide in human urine, *Curr. Med. Chem.* 11 (2004) 1085–1092.
- [31] N. Lane, *Oxygen, the Molecule that Made the World*, Oxford University Press, Oxford, UK, 2002.
- [32] J.M.C. Gutteridge, B. Halliwell, Oxidative stress, redox stress or redox success? *Biochem. Biophys. Res. Commun.* 502 (2018) 183–186.
- [33] Y.J. Taverne, D. Merkus, A.J. Bogers, B. Halliwell, D.J. Duncker, T.W. Lyons, Reactive oxygen species: radical factors in the evolution of animal life. A molecular timescale from earth's earliest history to the rise of complex life, *Bioessays* 40 (2018) 1700158.
- [34] S. Baskaran, R. Finelli, A. Agarwal, R. Henkel, Reactive oxygen species in male reproduction: a boon or a bane? *Andrologia* (2020), e13577.
- [35] G. Mohanty, L. Samanta, Redox regulation & sperm function: a proteomic insight, *Indian J. Med. Res.* 148 (Suppl) (2018) S84–S91.
- [36] L. Li, The relevance of mammalian peroxiredoxins to the gametogenesis, embryogenesis, and pregnancy outcomes, *Reprod. Sci.* 24 (2017) 812–817.
- [37] J. Lee, Y.S. Cho, H. Jung, I. Choi, Pharmacological regulation of oxidative stress in stem cells, *Oxid Med Cell Longev* 2018 (2018) 4081890.
- [38] E. Villamor, L. Moreno, R. Mohammed, F. Pérez-Vizcaíno, A. Cogolludo, Reactive oxygen species as mediators of oxygen signaling during fetal-to-neonatal circulatory transition, *Free Radic. Biol. Med.* 142 (2019) 82–96.
- [39] J.J. Fisher, L.A. Bartho, A.V. Perkins, O.J. Holland, Placental mitochondria and reactive oxygen species in the physiology and pathophysiology of pregnancy, *Clin. Exp. Pharmacol. Physiol.* 47 (2020) 176–184.
- [40] H.H. Yu, Y.H. Yang, B.L. Chiang, Chronic granulomatous disease: a comprehensive review, *Clin. Rev. Allergy Immunol.* (2020), <https://doi.org/10.1007/s12016-020-08800-x>.
- [41] J. Zhong, A. Yau, R. Holmdahl, Regulation of T Cell function by reactive nitrogen and oxygen species in collagen-induced arthritis, *Antioxidants Redox Signal.* 32 (2020) 161–172.
- [42] C.H. Foyer, B. Halliwell, The presence of glutathione and glutathione reductase in chloroplasts: a proposed role in ascorbic acid metabolism, *Planta* 133 (1976) 21–25.
- [43] H. Ding, B. Wang, Y. Han, S. Li, The pivotal function of dehydroascorbate reductase in glutathione homeostasis in plants, *J. Exp. Bot.* 71 (2020) 3405–3416.
- [44] M. Hossain, K. Asada, Ascorbate-regenerating enzymes in chloroplasts, *Indian J. Biochem. Biophys.* 24 (1987) suppl 52–s 56.
- [45] D. Groden, E. Beck, H<sub>2</sub>O<sub>2</sub> destruction by ascorbate-dependent systems from chloroplasts, *Biochim. Biophys. Acta* 546 (1979) 426–435.
- [46] S.A. Charles, B. Halliwell, Light activation of fructose biphosphatase in isolated spinach chloroplasts and deactivation by hydrogen peroxide: a physiological role for the thioredoxin system, *Planta* 151 (1981) 242–246.
- [47] L.A. Del Río, Redox pioneer: Professor Christine Helen Foyer, *Antioxidants Redox Signal.* 15 (2011) 2383–2391.
- [48] T. Oka, S. Hayashida, Y. Kaneda, M. Takenaga, Y. Tamagawa, S. Tsuji, A. Hatanaka, Green odor attenuates a cold pressor stress-induced cardiovascular response in healthy adults, *Biopsychosoc. Med.* 2 (2008) 2.
- [49] T. Durand, V. Bultel-Poncé, A. Guy, S. El Fanguor, J.C. Rossi, J.M. Galano, Isoprostanes and phytoestrogens: bioactive lipids, *Biochimie* 93 (2011) 52–60.
- [50] S. Nakamura, A. Hatanaka, Green-leaf-derived C6-araoma compounds with potent antibacterial action that act on both Gram-negative and Gram-positive bacteria, *J. Agric. Food Chem.* 50 (2002) 7639–7644.
- [51] Scientific opinion on dietary reference values for vitamin C – EFSA panel on dietetic products, nutrition and allergies (NDA), *EFSA J* 11 (2013) 3418.
- [52] A.C. Carr, B. Frei, Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans, *Am. J. Clin. Nutr.* 69 (1999) 1086–1107.
- [53] M. Levine, Y. Wang, S.J. Padayatty, J. Morrow, A new recommended dietary allowance of vitamin C for healthy young women, *Proc. Natl. Acad. Sci. U.S.A.* 98 (2001) 9842–9846.
- [54] J.A. Novotny, J.G. Fadel, D.M. Holstege, H.C. Furr, A.J. Clifford, The kinetic, bioavailability, and metabolism study of RRR- $\alpha$ -tocopherol in healthy adults suggests lower intake requirements than previous estimates, *J. Nutr.* 142 (2012) 2105–2111.
- [55] R.S. Bruno, S.W. Leonard, S.I. Park, Y. Zhao, M.G. Traber, Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled alpha-tocopheryl acetate, *Am. J. Clin. Nutr.* 83 (2006) 299–304.
- [56] J. McCleery, R.P. Abraham, D.A. Denton, A.W. Rutjes, L.Y. Chong, A.S. Al-Assaf, D.J. Griffith, S. Rafeeq, H. Yaman, M.A. Malik, M. Di Nisio, G. Martínez, R. W. Vernooij, N. Tabet, Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment, *Cochrane Database Syst. Rev.* 11 (2018) CD011905.
- [57] R. Asleh, A. Briasoulis, E.M. Berinstein, J.B. Wiener, M. Palla, S.S. Kushwaha, A. P. Levy, Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation, *Pharmacogenomics Personalized Med.* 11 (2018) 71–82.
- [58] M. Goodman, R.M. Bostick, O. Kucuk, D.P. Jones, Clinical trials of antioxidants as cancer prevention agents: past, present, and future, *Free Radic. Biol. Med.* 51 (2011) 1068–1084.
- [59] N. Farina, D. Llewellyn, M.G.E.K.N. Isaac, N. Tabet, Vitamin E for Alzheimer's dementia and mild cognitive impairment, *Cochrane Database Syst. Rev.* 4 (2017) CD002854.
- [60] T.A. Hore, F. von Meyenn, M. Ravichandran, M. Bachman, G. Ficz, D. Oxley, F. Santos, S. Balasubramanian, T.P. Jurkowski, W. Reik, Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to naïve pluripotency by complementary mechanisms, *Proc. Natl. Acad. Sci. U.S.A.* 113 (2016) 12202–12207.
- [61] D. Mastrangelo, E. Pelosi, G. Castelli, F. Lo-Coco, U. Testa, Mechanisms of anti-cancer effects of ascorbate: cytotoxic activity and epigenetic modulation, *Blood Cells Mol. Dis.* 69 (2018) 57–64.
- [62] B. Halliwell, Artefacts with ascorbate and other redox-active compounds in cell culture: epigenetic modifications, and cell killing due to hydrogen peroxide generation in cell culture media, *Free Radic. Res.* 52 (2018) 907–909.
- [63] C.E. Cross, A. van der Vliet, S. Louie, J.J. Thiele, B. Halliwell, Oxidative stress and antioxidants at biosurfaces: plants, skin and respiratory tract surfaces, *Environ. Health Perspect.* 106 (suppl 5) (1998) 1241–1251.
- [64] D. Gao, S. Ripley, S. Weichenthal, K.J.G. Pollitt, Ambient particulate matter oxidative potential: chemical determinants, associated health effects, and strategies for risk management, *Free Radic. Biol. Med.* 151 (2020) 7–25.
- [65] B. Halliwell, Oxidative stress and cancer: have we moved forward? *Biochem. J.* 401 (2007) 1–11.
- [66] J.D. Hayes, A.T. Dinkova-Kostova, K.D. Tew, Oxidative stress in cancer, *Canc. Cell* 38 (2020) 167–197.
- [67] G.M. Aceto, T. Catalano, M.C. Curia, Molecular aspects of colorectal adenomas: the interplay among microenvironment, oxidative stress, and predisposition, *BioMed Res. Int.* 2020 (2020) 1726309.
- [68] D.A. Butterfield, B. Halliwell, Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease, *Nat. Rev. Neurosci.* 20 (2019) 148–160.
- [69] A. Höhn, A. Tramutola, R. Cascella, Proteostasis failure in neurodegenerative diseases: focus on oxidative stress, *Oxid. Med. Cell. Longev.* 5497046 (2020), <https://doi.org/10.1155/2020/5497046>.
- [70] G. Veurink, G. Perry, S.K. Singh, Role of antioxidants and a nutrient rich diet in Alzheimer's disease, *Open Biology* 10 (2020) 200084.
- [71] D.A. Butterfield, Brain lipid peroxidation and Alzheimer disease: synergy between the Butterfield and Mattson laboratories, *Ageing Res. Rev.* 20 (2020) 101049, <https://doi.org/10.1016/j.arr.2020.101049>.
- [72] P. Jenner, Oxidative stress in Parkinson's disease, *Ann. Neurol.* 53 (Suppl 3) (2003) S26–S38.



- [73] R.C. Seet, C.Y. Lee, E.C. Lim, J.J. Tan, A.M. Quek, W.L. Chong, W.F. Looi, S. H. Huang, H. Wang, Y.H. Chan, B. Halliwell, Oxidative damage in Parkinson disease: measurement using accurate biomarkers, *Free Radic. Biol. Med.* 48 (2010) 560–566.
- [74] K.H. Chang, C.M. Chen, The role of oxidative stress in Parkinson's disease, *Antioxidants* 9 (2020) 597.
- [75] N.V. Margaritelis, V. Paschalis, A.A. Theodorou, A. Kyparos, M.G. Nikolaidis, Antioxidant supplementation, redox deficiencies and exercise performance: a falsification design, *Free Radic. Biol. Med.* 158 (2020) 44–52.
- [76] B. Halliwell, Free radicals and antioxidants: updating a personal view, *Nutr. Rev.* 70 (2012) 257–265.
- [77] B. Halliwell, Free radicals and antioxidants: - quo vadis? *Trends Pharmacol. Sci.* 32 (2011) 125–130.
- [78] B. Halliwell, The antioxidant paradox: less paradoxical now? *Br. J. Clin. Pharmacol.* 75 (2013) 637–644.
- [79] H. Priemé, S. Loft, K. Nyyssönen, J.T. Salonen, H.E. Poulsen, No effect of supplementation with vitamin E, ascorbic acid, or coenzyme Q10 on oxidative DNA damage estimated by 8-oxo-7,8-dihydro-2'-deoxyguanosine excretion in smokers, *Am. J. Clin. Nutr.* 65 (1997) 503–507.
- [80] J.D. O'Reilly, A.I. Mallet, G.T. McAnlis, I.S. Young, B. Halliwell, T.A.B. Sanders, H. Wiseman, Consumption of flavonoids in onions and black tea; Lack of effect on F<sub>2</sub>-isoprostanes and autoantibodies to oxidized LDL in healthy humans, *Am. J. Clin. Nutr.* 73 (2001) 1040–1044.
- [81] R. Kelly, K.P. Yeo, H. Isaac, J.C. Lee, S.H. Huang, L. Teng, B. Halliwell, S.D. Wise, Lack of effect of acute oral ingestion of vitamin C on oxidative stress, arterial stiffness or blood pressure in healthy subjects, *Free Radic. Res.* 42 (2008) 514–522.
- [82] M.J. Jackson, C. Stretton, A. McArdle, Hydrogen peroxide as a signal for skeletal muscle adaptations to exercise: what do concentrations tell us about potential mechanisms? *Redox Biol* 35 (2020) 101484.
- [83] E. Latz, NOX-free inflammasome activation, *Blood* 116 (2010) 1393–1394.
- [84] S.K. Powers, R. Deminice, M. Ozdemir, T. Yoshihara, M.P. Bomkamp, H. Hyatt, Exercise-induced oxidative stress: friend or foe?, 30039-9, *J Sport Health Sci* S2095–2546 (20) (2020), <https://doi.org/10.1016/j.jshs.2020.04.001> (Online ahead of print).
- [85] H. Brendel, A. Shahid, A. Hofmann, J. Mittag, S.R. Bornstein, H. Morawietz, C. Brunsen, NADPH oxidase 4 mediates the protective effects of physical activity against obesity-induced vascular dysfunction, *Cardiovasc. Res.* 116 (2020) 1767–1778.
- [86] C.Y. Lee, H.B. Isaac, H. Wang, S.H. Huang, L.H. Long, A.M. Jenner, R.P. Kelly, B. Halliwell, Cautions in the use of biomarkers of oxidative damage; the vascular and antioxidant effects of dark soy sauce in humans, *Biochem. Biophys. Res. Commun.* 344 (2006) 906–911.
- [87] M.N. Vißers, P.L. Zock, R. Leenen, A.J. Roodenburg, K.P. van Putte, M.B. Katan, Effect of consumption of phenols from olives and extra virgin olive oil on LDL oxidizability in healthy humans, *Free Radic. Res.* 35 (2001) 619–629.
- [88] H. Chen, Y. He, S. Chen, S. Qi, J. Shen, Therapeutic targets of oxidative/nitrosative stress and neuroinflammation in ischemic stroke: applications for natural product efficacy with omics and systemic biology, *Pharmacol. Res.* 158 (2020) 104877.
- [89] J. Minnerup, B.A. Sutherland, A.M. Buchan, C. Kleinschitz, Neuroprotection for stroke: current status and future perspectives, *Int. J. Mol. Sci.* 13 (2012) 11753–11772.
- [90] M.R. Macleod, H.B. van der Worp, E.S. Sena, D.W. Howells, U. Dirnagl, G. A. Donnan, Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality, *Stroke* 39 (2008) 2824–2829.
- [91] A. Schmidt-Pogoda, N. Bonberg, M.H.M. Koecke, J.K. Strecker, J. Wellmann, N. M. Bruckmann, C. Beuker, W.R. Schäbitz, S.G. Meuth, H. Wiendl, H. Minnerup, J. Minnerup, Why most acute stroke studies are positive in animals but not in patients: a systematic comparison of preclinical, early phase, and phase 3 clinical trials of neuroprotective agents, *Ann. Neurol.* 87 (2020) 40–51.
- [92] R.C.S. Seet, C.Y.J. Lee, P.L. Chan, V.K. Sharma, H.L. Teoh, N. Venketasubramanian, C.H. Lim, W.L. Chong, W.F. Looi, S.H. Huang, K.C. Ong, B. Halliwell, Oxidative damage in ischemic stroke revealed using multiple biomarkers, *Stroke* 42 (2011) 2326–2329.
- [93] R.C. Seet, C.Y. Lee, W.M. Loke, S.H. Huang, H. Huang, W.F. Looi, E.S. Chew, A. M. Quek, E.C. Lim, B. Halliwell, Biomarkers of oxidative damage in cigarette smokers: which biomarkers might reflect acute versus chronic oxidative stress? *Free Radic. Biol. Med.* 50 (2011) 1787–1793.
- [94] J. Gruber, S.Y. Tang, A.M. Jenner, I. Mudway, A. Blomberg, A. Behndig, K. Kasiman, C.Y. Lee, R.C. Seet, W. Zhang, C. Chen, F. Kelly, B. Halliwell, Allantoin in human plasma, serum and nasal lining fluids as a biomarker of oxidative stress; avoiding artifacts and establishing real in vivo concentrations, *Antioxidants Redox Signal.* 11 (2009) 1767–1776.
- [95] G.L. Milne, Q. Dai, L.J. Roberts 2nd, The isoprostanes-25 years later, *Biochim. Biophys. Acta* 1851 (2015) 433–445.
- [96] H. Wang, S. Schoebel, F. Schmitz, H. Dong, K. Hedfalk, Quantitative analysis of H<sub>2</sub>O<sub>2</sub> transport through purified membrane proteins, *Methods (Orlando)* 7 (2020) 100816.
- [97] B. Halliwell, J.M.C. Gutteridge, *Free Radicals in Biology and Medicine*, fourth ed., Clarendon Press, Oxford, 2007. UK.
- [98] B. Halliwell, J.M.C. Gutteridge, The importance of free radicals and catalytic metal ions in human disease, *Mol. Aspects. Med.* 8 (1985) 89–193.
- [99] B. Halliwell, J.M.C. Gutteridge, Oxygen toxicity, oxygen radicals, transition metals and disease, *Biochem. J.* 219 (1984) 1–14.
- [100] B. Halliwell, J.M.C. Gutteridge, The antioxidants of human extracellular fluids, *Arch. Biochem. Biophys.* 280 (1990) 1–8.
- [101] J.M.C. Gutteridge, B. Halliwell, Antioxidants: molecules, medicines and myths, *Biochem. Biophys. Res. Commun.* 393 (2010) 561–564.
- [102] B. Halliwell, O.I. Aruoma, G. Mufti, A. Bomford, Bleomycin-detectable iron in serum from leukaemic patients before and after chemotherapy. Therapeutic implications for treatment with oxidant-generating drugs, *FEBS Lett.* 241 (1988) 202–204.
- [103] T.C. Carmine, P. Evans, G. Bruchelt, R. Evans, R. Handgretinger, D. Niethammer, B. Halliwell, Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management, *Canc. Lett.* 94 (1995) 219–226.
- [104] P.J. Evans, R. Evans, I.Z. Kovar, A.F. Holton, B. Halliwell, Bleomycin-detectable iron in the plasma of premature and full-term neonates, *FEBS Lett.* 303 (1992) 210–212.
- [105] P.J. Evans, R.W. Evans, A. Bomford, R. Williams, B. Halliwell, Metal ions catalytic for free radical reactions in the plasma of patients with fulminant hepatic failure, *Free Radic. Res.* 20 (1994) 139–144.
- [106] O.I. Aruoma, A. Bomford, R.J. Polson, B. Halliwell, Non-transferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy, *Blood* 72 (1988) 1416–1419.
- [107] C. Matayatsuk, C.Y. Lee, R.W. Kalpravidh, P. Sirankapracha, P. Wilairat, S. Fuchareon, B. Halliwell, Elevated F<sub>2</sub>-isoprostanes in thalassemic patients, *Free Radic. Biol. Med.* 43 (2007) 1649–1655.
- [108] Z.I. Cabantchik, W. Breuer, G. Zanninelli, P. Cianciulli, LPI-labile plasma iron in iron overload, *Best Pract. Res. Clin. Haematol.* 18 (2005) 277–287.
- [109] J.M.C. Gutteridge, D.A. Rowley, E. Griffiths, B. Halliwell, Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis, *Clin. Sci.* 68 (1985) 463–467.
- [110] J.M.C. Gutteridge, R. Richmond, B. Halliwell, Inhibition of iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine, *Biochem. J.* 184 (1979) 469–472.
- [111] P. Holden, L.S. Nair, Deferoxamine: an angiogenic and antioxidant molecule for tissue regeneration, *Tissue Eng. B Rev.* 25 (2019) 461–470.
- [112] B. Halliwell, Protection against tissue damage *in vivo* by desferrioxamine: what is its mechanism of action? *Free Radic. Biol. Med.* 7 (1989) 645–651.
- [113] M. Selim, L.D. Foster, C.S. Moy, G. Xi, M.D. Hill, L.B. Morgenstern, S. M. Greenberg, M.L. James, V. Singh, W.M. Clark, C. Norton, Y.Y. Palesch, S. D. Yeatts, i-Def Investigators, Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial, *Lancet Neurol.* 18 (2019) 428–438.
- [114] X. Zhao, M. Kruzel, S.M. Ting, G. Sun, S.I. Savitz, J. Aronowski, Optimized lactoferrin as a highly promising treatment for intracerebral hemorrhage: pre-clinical experience, *J. Cerebr. Blood Flow Metabol.* 21 (2020), 271678X20925667.
- [115] D.B. Kell, E.L. Heyden, E. Pretorius, The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria, *Front. Immunol.* 11 (2020) 1221.
- [116] C. Guo, H. Xue, T. Guo, W. Zhang, W.Q. Xuan, Y.T. Ren, D. Wang, Y.H. Chen, Y. H. Meng, H.L. Gao, P. Zhao, Recombinant human lactoferrin attenuates the progression of hepatosteatosis and hepatocellular death by regulating iron and lipid homeostasis in ob/ob mice, *Food Funct* (2020), <https://doi.org/10.1039/d0fo00910e> (Online ahead of print).
- [117] J.M. Gutteridge, S.K. Paterson, A.W. Segal, B. Halliwell, Inhibition of lipid peroxidation by the iron-binding protein lactoferrin, *Biochem. J.* 199 (1981) 259–261.
- [118] O.I. Aruoma, B. Halliwell, Superoxide-dependent and ascorbate-dependent formation of hydroxyl radicals from hydrogen peroxide in the presence of iron. Are lactoferrin and transferrin promoters of hydroxyl-radical generation? *Biochem. J.* 241 (1987) 273–278.
- [119] A. Martin-Bastida, R.J. Ward, R. Newbould, P. Piccini, D. Sharp, C. Kabba, M. C. Patel, M. Spino, J. Connelly, F. Tricta, R.R. Crichton, D.T. Dexter, Brain iron chelation by deferiprone in a phase 2 randomised double-blind placebo controlled clinical trial in Parkinson's disease, *Sci. Rep.* 7 (2017) 1398.
- [120] A. Shahandeh, B.V. Bui, D.I. Finkelstein, C.T.O. Nguyen, Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina, *J. Neurosci. Res.* 98 (2020) 1889–1904.
- [121] H.A. Wetli, P.D. Buckett, M. Wessling-Resnick, Small-molecule screening identifies the selanzal drug ebelsen as a potent inhibitor of DMT1-mediated iron uptake, *Chem. Biol.* 13 (2006) 965–972.
- [122] L. Xie, W. Zheng, N. Xin, J.W. Xie, T. Wang, Z.Y. Wang, Ebelsen inhibits iron-induced tau phosphorylation by attenuating DMT1 up-regulation and cellular iron uptake, *Neurochem. Int.* 61 (2012) 334–340.
- [123] B.R. Stockwell, X. Jiang, W. Gu, Emerging mechanisms and disease relevance of ferroptosis, *Trends Cell Biol.* 30 (2020) 478–490.
- [124] Y. Qiu, Y. Cao, W. Cao, Y. Jia, N. Lu, The application of ferroptosis in diseases, *Pharmacol. Res.* 159 (2020) 104919.
- [125] L. Mao, T. Zhao, Y. Song, L. Lin, X. Fan, B. Cui, H. Feng, X. Wang, Q. Yu, J. Zhang, K. Jiang, B. Wang, C. Sun, The emerging role of ferroptosis in non-cancer liver diseases: hype or increasing hope? *Cell Death Dis.* 11 (2020) 518.
- [126] C.W. Brown, J.J. Amante, P. Chhoy, A.L. Elaimy, H. Liu, L.J. Zhu, C.E. Baer, S. J. Dixon, A.M. Mercurio, Prominin2 drives ferroptosis resistance by stimulating iron export, *Dev. Cell* 51 (2019) 575–586, e4.
- [127] C. Mukherjee, T. Kling, B. Russo, K. Miebach, E. Kess, M. Schifferer, L.D. Pedro, U. Weikert, M.K. Fard, N. Kannaiyan, M. Rossner, M.L. Aicher, S. Goebbels, K. A. Nave, E.M. Krämer-Albers, A. Schneider, M. Simons, Oligodendrocytes provide

- antioxidant defense function for neurons by secreting ferritin heavy chain, *Cell Metabol.* 32 (2020) 259–272, e10.
- [128] S.M. Sadrzadeh, E. Graf, S.S. Panter, P.E. Hallaway, J.W. Eaton, Hemoglobin. A biologic Fenton reagent, *J. Biol. Chem.* 259 (1984) 14354–14356.
- [129] M. Hugelshofer, R.M. Buzzi, C.A. Schaefer, H. Richter, K. Akeret, V. Anagnostakou, L. Mahmoudi, R. Vaccani, F. Vallelian, J.W. Deuel, P.W. Kronen, Z. Kulcsar, L. Regli, J.H. Baek, I.S. Pires, A.F. Palmer, M. Denner, R. Humar, P.W. Buehler, P. R. Kircher, E. Keller, D.J. Schaer, Haptoglobin administration into the subarachnoid space prevents hemoglobin-induced cerebral vasospasm, *J. Clin. Invest.* 129 (2019) 5219–5235.
- [130] M. Guerrero-Hue, C. García-Caballero, A. Palomino-Antolín, A. Rubio-Navarro, C. Vázquez-Carballo, C. Herencia, D. Martín-Sánchez, V. Farré-Alins, J. Egea, P. Cannata, M. Praga, A. Ortiz, J. Egido, A.B. Sanz, J.A. Moreno, Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death, *Faseb. J.* 33 (2019) 8961–8975.
- [131] L. Eddy, A. Arduini, P. Hochstein, Reduction of ferrylmyoglobin in rat diaphragm, *Am. J. Physiol.* 259 (1990) C995–C997.
- [132] J. Simoni, J. Villanueva-Meyer, G. Simoni, J.F. Moeller, D.E. Wesson, Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system, *Artif. Organs* 33 (2009) 115–126.
- [133] J.M. Gutteridge, Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides, *FEBS Lett.* 201 (1986) 291–295.
- [134] A. Puppo, K. Groten, F. Bastian, R. Carzaniga, M. Soussi, M.M. Lucas, M.R. de Felipe, J. Harrison, H. Vanacker, C.H. Foyer, Legume nodule senescence: roles for redox and hormone signalling in the orchestration of the natural aging process, *New Phytol.* 165 (2005) 683–701.
- [135] H. Kaur, I. Fagerheim, M. Grootveld, A. Puppo, B. Halliwell, Aromatic hydroxylation of phenylalanine as an assay for hydroxyl radicals: application to activated human neutrophils and to the heme protein leghemoglobin, *Anal. Biochem.* 172 (1988) 360–367.
- [136] A. Puppo, B. Halliwell, Oxidation of dimethylsulphoxide to formaldehyde by oxyhaemoglobin and oxyleghaemoglobin in the presence of hydrogen peroxide is not mediated by “free” hydroxyl radicals, *Free Radic. Res. Commun.* 5 (1989) 277–281.
- [137] L. Oldach, *Biochemistry of a Burger*, ASBMB Today, 2019, pp. 32–39.
- [138] R.Z. Fraser, M. Shitut, P. Agrawal, O. Mendes, S. Klapholz, Safety evaluation of soy leghemoglobin protein preparation derived from *Pichia pastoris*, intended for use as a flavor catalyst in plant-based meat, *Int. J. Toxicol.* 37 (2018) 241–262.
- [139] L.Y. Hemeryck, C. Rombouts, E. De Paepe, L. Vanhaecke, DNA adduct profiling of in vitro colonic meat digests to map red vs. white meat genotoxicity, *Food Chem.* 115 (2018) 73–87.
- [140] A. Macho-González, A. Garcimartín, M.E. López-Oliva, S. Bastida, J. Benedí, G. Ros, G. Nieto, F.J. Sánchez-Muniz, Can meat and meat-products induce oxidative stress? *Antioxidants* 9 (2020) 638.
- [141] F. Qian, M.C. Riddle, J. Wylie-Rosett, F.B. Hu, Red and processed meats and health risks: how strong is the evidence? *Diabetes Care* 43 (2020) 265–271.
- [142] N.K. Gopaul, B. Halliwell, E.E. Anggard, Measurement of plasma F<sub>2</sub>-isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet, *Free Radic. Res.* 33 (2000) 115–127.
- [143] I. Cheah, B. Halliwell, Ergothioneine; antioxidant potential, physiological function and role in disease, *Biochim. Biophys. Acta* 1822 (2012) 784–793.
- [144] B. Halliwell, I.K. Cheah, R. Tang, Ergothioneine - a diet-derived antioxidant with therapeutic potential, *FEBS Lett.* 592 (2018) 3357–3366.
- [145] I. Borodina, L.C. Kenny, C.M. McCarthy, K. Paramasivan, E. Pretorius, T. J. Roberts, S.A. van der Hoek, D.B. Kell, The biology of ergothioneine, an antioxidant nutraceutical, *Nutr. Res. Rev.* 13 (2020) 1–28, <https://doi.org/10.1017/S0954422419000301>. Advance online publication.
- [146] D.B. Melville, C.C. Otken, V. Kovalenko, On the origin of animal ergothioneine, *J. Biol. Chem.* 216 (1955) 325–331.
- [147] H. Kawano, M. Otani, K. Takeyama, Y. Kawai, T. Mayumi, T. Hama, Studies on ergothioneine. VI. Distribution and fluctuations of ergothioneine in rats, *Chem. Pharm. Bull.* 30 (1982) 1760–1765.
- [148] M. Muda, F. Pelizzoni, G. Sello, E. Mussini, Determination of ergothioneine in red blood cells by high-performance liquid chromatography, *J. Chromatogr.* 434 (1988) 191–195.
- [149] O.I. Aruoma, M. Whiteman, T.G. England, B. Halliwell, Antioxidant action of ergothioneine: assessment of its ability to scavenge peroxynitrite, *Biochem. Biophys. Res. Commun.* 231 (1997) 389–391.
- [150] D. Akanmu, R. Cecchini, O.I. Aruoma, B. Halliwell, The antioxidant action of ergothioneine, *Arch. Biochem. Biophys.* 288 (1991) 10–16.
- [151] D. Gründemann, S. Harlfinger, S. Golz, A. Geerts, A. Lazar, R. Berkels, N. Jung, A. Rubbert, E. Schömig, Discovery of the ergothioneine transporter, *Proc. Natl. Acad. Sci. U.S.A.* 102 (2005) 5256–5261.
- [152] J. Tschirka, M. Kreisor, J. Betz, D. Gründemann, Substrate selectivity check of the ergothioneine transporter, *Drug Metab. Dispos.* 46 (2018) 779–785.
- [153] R. Tucker, I.K. Cheah, B. Halliwell, Specificity of the ergothioneine transporter natively expressed in HeLa cells, *Biochem. Biophys. Res. Commun.* 513 (2019) 22–27.
- [154] B. Halliwell, I.K. Cheah, C.L. Drum, Ergothioneine, an adaptive antioxidant for the protection of injured tissues? A hypothesis, *Biochem. Biophys. Res. Commun.* 470 (2016) 245–250.
- [155] R. Tang, I.K. Cheah, T. Yew, B. Halliwell, Distribution and accumulation of dietary ergothioneine and its metabolites in mouse tissues, *Sci. Rep.* 8 (2018) 1601.
- [156] I.K. Cheah, R.M. Tang, T.S. Yew, K.H. Lim, B. Halliwell, Administration of pure ergothioneine to healthy human subjects: uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation, *Antioxidants Redox Signal.* 26 (2017) 193–206.
- [157] I.K. Cheah, L.T. Ng, L.F. Ng, V.Y. Lam, J. Gruber, C.Y.W. Huang, F.Q. Goh, K.H. C. Lim, B. Halliwell, Inhibition of amyloid-induced toxicity by ergothioneine in a transgenic *Caenorhabditis elegans* model, *FEBS Lett.* 593 (2019) 2139–2150.
- [158] M. Kameda, T. Teruya, M. Yanagida, H. Kondoh, Frailty markers comprise blood metabolites involved in antioxidation, cognition, and mobility, *Proc. Natl. Acad. Sci. U.S.A.* 117 (2020) 9483–9489.
- [159] J.L. Nierenberg, J. He, C. Li, X. Gu, M. Shi, A.C. Razavi, X. Mi, S. Li, L.A. Bazzano, A.H. Anderson, H. He, W. Chen, J.M. Guralnik, J.M. Kinchen, T.N. Kelly, Serum metabolites associate with physical performance among middle-aged adults: evidence from the Bogalusa heart study, *Aging* 12 (2020) 11914–11941.
- [160] H. Kondoh, T. Teruya, M. Yanagida, Metabolomics of human fasting: new insights about old questions, *Open Biol* 10 (2020) 200176.
- [161] B.N. Ames, Prolonging healthy aging: longevity vitamins and proteins, *Proc. Natl. Acad. Sci. U.S.A.* 115 (2018) 10836–10844.
- [162] C.Y. Lee, H.B. Isaac, S.H. Huang, L.H. Long, H. Wang, J. Gruber, C.N. Ong, R. P. Kelly, Halliwell B. Kelly, Limited antioxidant effect after consumption of a single dose of tomato sauce by young males, despite a rise in plasma lycopene, *Free Radic. Res.* 43 (2009) 622–628.
- [163] F. Thies, L.M. Mills, S. Moir, L.F. Masson, Cardiovascular benefits of lycopene: fantasy or reality? *Proc. Nutr. Soc.* 76 (2017) 122–129.
- [164] B. Halliwell, Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life, *Plant Physiol.* 141 (2006) 312–322.
- [165] P.B. Pun, J. Gruber, S.Y. Tang, S. Schaffer, R.L. Ong, S. Fong, L.F. Ng, I. Cheah, B. Halliwell, Ageing in nematodes: do antioxidants extend lifespan in *Caenorhabditis elegans*? *Biogerontology* 11 (2010) 17–30.
- [166] E. Teo, K. Chaitanya, D. Barardo, L.F. Xiao, A. Cazenave-Gassiot, N. Tolwinski, M. Wenk, B. Halliwell, J. Gruber, A novel vibration-induced exercise paradigm improves fitness and lipid metabolism of *Caenorhabditis elegans*, *Sci. Rep.* 8 (2018) 9420.
- [167] I.K. Cheah, L. Feng, R.M. Tang, K.H. Lim, B. Halliwell, Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration? *Biochem. Biophys. Res. Commun.* 478 (2016) 162–167.